Reviewing XOMA Corporation (XOMA)’s and Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s results

We will be comparing the differences between XOMA Corporation (NASDAQ:XOMA) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) as far as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XOMA Corporation 25 -5.73 5.84M -0.12 0.00
Adaptive Biotechnologies Corporation 30 0.00 61.12M 0.07 427.35

Table 1 highlights XOMA Corporation and Adaptive Biotechnologies Corporation’s gross revenue, earnings per share and valuation.


Table 2 provides us XOMA Corporation and Adaptive Biotechnologies Corporation’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
XOMA Corporation 22,974,036.19% -9% -2.7%
Adaptive Biotechnologies Corporation 207,116,231.79% 0% 0%


XOMA Corporation’s Current Ratio and Quick Ratio are 4.4 and 4.4 respectively. The Current Ratio and Quick Ratio of its competitor Adaptive Biotechnologies Corporation are 8.2 and 8.1 respectively. Adaptive Biotechnologies Corporation therefore has a better chance of paying off short and long-term obligations compared to XOMA Corporation.

Insider and Institutional Ownership

The shares of both XOMA Corporation and Adaptive Biotechnologies Corporation are owned by institutional investors at 43% and 65.7% respectively. Insiders owned roughly 0.3% of XOMA Corporation’s shares. Comparatively, insiders own roughly 4.7% of Adaptive Biotechnologies Corporation’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XOMA Corporation 4.13% 12.39% 39.82% 45.74% 70.84% 101.5%
Adaptive Biotechnologies Corporation 6.88% 8.51% -26.39% 0% 0% -27.89%

For the past year XOMA Corporation has 101.5% stronger performance while Adaptive Biotechnologies Corporation has -27.89% weaker performance.


Adaptive Biotechnologies Corporation beats on 10 of the 11 factors XOMA Corporation.

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.